|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Multiple Myeloma - Exploring new targets for multiple drug therapy
Datamonitor, Dec 2007, Pages: 107
The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson)has significantly advanced treatment.
Scope
- Multiple myeloma epidemiology, disease features and progress in current treatment
- Remaining unmet needs in the treatment of multiple myeloma
- Research and analysis of the multiple myeloma pipeline with in-depth clinical and commercial assessment of Phase III drug candidates
- Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU
Highlights of this title
The approval of three new agents, Thalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson), has significantly changed the MM treatment approach for both newly diagnosed and relapsed/refractory disease.
Despite the recent advances in treatment, MM remains largely incurable as disease relapse is inevitable. There remains a strong need for more efficacious and tolerable drugs that affect new therapeutic targets and enhance patient outcomes.
There is great opportunity for novel agents to enter the myeloma market as patients often require multiple lines of therapy. Furthermore, the major approach to myeloma drug therapy is the use of combined regimens. A drug that shows potential synergistic activity with other approved or emerging drugs would be well received.
Key reasons to purchase this title
- Gain an insight into the epidemiology trends and disease characteristics of multiple myeloma
- Analyze the current status of multiple myeloma treatment and consider the remaining unmet needs
- Acquire a detailed appreciation and impartial perspective of the multiple myeloma pipeline and identify the key products in late-phase development
Customers who bought this item also bought
Multiple Myeloma Therapeutics - Global Strategic Business Report
Multiple Myeloma Therapeutics - US Market Trends & Analysis
Multiple Myeloma Therapeutics - US Market Trends & Analysis
U.S. Multiple Myeloma Market
Cancer Multiple Myeloma
Multiple Myeloma Drug Pipeline Report
Multiple Myeloma Therapy Area Pipeline Report
Revlimid Wave 3 Tracking Survey; Trends in Usage in Multiple Myeloma and myelodysplastic syndrome - A Survey of Fifty One Oncologists and Hematologists
Innovations and Trends in Clinical Trials - Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
Molecular-Targeted Pharmacotherapy in Myeloma: Clinical and Strategic Challenges on the Road to Commercialization
Trial TRAX - Multiple Sclerosis - Clinical Trial Monitoring Brief
Prospects for the Phase III Bapineuzumab Trial
|
|
|
|
